# ERADICATE (NCT07198724)

> ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07198724
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Kristina A. Fanucci
- Conditions: Metastatic Breast Cancer; HER2 Low Breast Carcinoma; HER2-negative Breast Cancer; Breast Cancer; Breast Cancer Female
- Interventions: Elacestrant; Trastuzumab Deruxtecan
- Enrollment: 65
- Primary outcome: Recommended phase II dose (RP2D)
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=eradicate-nct07198724